Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Arcus Biosciences, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 142 | 157 | +15 |
| Shares | 50.8M | 50.6M | −201.2K (−0.4%) |
| Value | $2.06B | $1.60B | −$458.0M (−22.3%) |
New holders (34)
Institutions that held Arcus Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (19)
Institutions that held Arcus Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Healthcare of Ontario Pension Plan Trust Fund | 370,597 | $15.0M |
| Two Sigma Investments, LP | 160,336 | $6.49M |
| Balyasny Asset Management LLC | 149,730 | $6.06M |
| Voloridge Investment Management, LLC | 94,938 | $3.84M |
| EAM Investors, LLC | 76,163 | $3.08M |
| Toronto Dominion Bank | 56,013 | $2.27M |
| EAM Global Investors LLC | 49,498 | $2.00M |
| Cooper Creek Partners Management LLC | 28,342 | $1.15M |
| Schonfeld Strategic Advisors LLC | 24,900 | $1.01M |
| Natixis | 15,100 | $611.0K |
| Verition Fund Management LLC | 11,455 | $464.0K |
| Caxton Associates LP | 11,387 | $461.0K |
| Wexford Capital LP | 9,800 | $397.0K |
| Jump Financial, LLC | 9,783 | $396.0K |
| Winton Group Ltd | 6,910 | $280.0K |
| Quantamental Technologies LLC | 5,793 | $234.0K |
| PDT Partners, LLC | 5,051 | $204.0K |
| TriaGen Wealth Management LLC | 5,000 | $202.0K |
| CWM, LLC | 10 | $0 |